Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TNF (adalimumab) repurposing for Dupuytren's disease
ISRCTN27786905Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial of adalimumab in Dupuytren's contracture (4 arms), sponsored by University of Oxford. Primary endpoints: Expression of mRNA for alpha-smooth muscle actin and Nodule hardness by tonometry. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
Dupuytren's contracture
Beyond the preview
Go deeper on ISRCTN27786905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN27786905.